News & Events

May 20

LumaCyte’s upcoming webinar will explore how patient‑centric clinical trials and next‑generation analytical technologies are reshaping the future of healthcare innovation, expanding on themes from our recent LinkedIn update about improving patient experience, strengthening trial design, and accelerating therapeutic development. Join industry experts as they discuss how advanced, label‑free cellular analytics like Laser Force Cytology™ can support smarter, more adaptive clinical strategies and help bring safer, more effective therapies to patients faster. Register for the webinar to reserve your spot.

May 6-9

LumaCyte recently attended ISCT 2026, joining global leaders in cell and gene therapy to advance the conversation around next‑generation analytics and manufacturing innovation. Throughout the event, the team highlighted how Laser Force Cytology™, powered by Radiance®, is enabling deeper functional insight, stronger process understanding, and more reliable product quality across advanced therapy programs. It was an energizing week of scientific exchange, and we look forward to continuing these collaborations as the field accelerates toward more precise, scalable, and patient‑focused cell and gene therapy development.

March 22

LumaCyte CEO & CSO Dr. Sean Hart has been invited to deliver the ACS BIOT 2026 Keynote in Atlanta, where he will highlight how real‑time, label‑free cellular PAT analytics combined with predictive modeling and machine learning are reshaping ATMP development and manufacturing. His talk will explore how next‑generation analytical approaches strengthen quality, improve yield, and support more reliable potency across programs. Read more in our LinkedIn announcement.

March 12

At Phacilitate’s Advanced Therapies Week, LumaCyte President & CBO Renee Hart joined Phacilitate TV to discuss why next‑generation analytical platforms and predictive modeling are essential to the future of advanced biomanufacturing. She highlighted how high‑resolution, real‑time cellular insight strengthens control, supports regulatory expectations, and ultimately drives more consistent therapeutic performance. Watch the full interview here!

February 17-19

LumaCyte President & CBO, Renee Hart, will deliver an invited talk at the Blood Centers of America Annual Meeting, focusing on donor cell qualification and the use of predictive cell function analytics to drive improvements in advanced cellular therapies. Her presentation will highlight how quantitative cellular characterization strengthens assessments of cell quality, vitality, and potency to support more consistent, potent, and safer therapeutic products.

February 9–12

LumaCyte participated in Phacilitate’s Advanced Therapies Week alongside leaders shaping the future of cell and gene therapies, emphasizing how label‑free, single‑cell measurements power robust machine learning and predictive modeling that are transforming ATMP development and manufacturing. The team highlighted how real‑time, quantitative cellular characterization improves donor and starting‑material assessment, reduces variability, and supports more consistent therapeutic performance across the entire process—from in‑process monitoring and vitality assessment to robust potency prediction. See event highlights and insights in our LinkedIn recap.

January 13

GEN highlights how LumaCyte’s Laser Force Cytology™ is transforming cell therapy manufacturing by delivering real‑time, quantitative insight into cell health and process performance. In the feature, CEO Sean Hart discusses how advanced, label‑free analytics are reducing manufacturing failures, improving process control, and expanding patient access by making cell therapy production more predictable and scalable. Read more.

December 1-3

LumaCyte is heading to the 7th Cell Therapy Analytical Development Summit in Boston, MA, December 1–3, 2025, to showcase how Laser Force Cytology™ is revolutionizing cell therapy analytics with real-time, label-free insights that enhance precision, safety, and consistency across CGT manufacturing.

November 19

LumaCyte’s President & CBO Renee Hart will join seven other global experts at the Novo Nordisk Foundation Cellerator’s Cell Therapy Insight Series, co-hosted with Thermo Fisher Scientific, for a full-day event on IND/CTA strategy for early-stage cell therapy and biotech teams in Hellerup, Denmark.

October 28–30

Meet LumaCyte’s Dr. Christof Hasse at CPHI Frankfurt 2025, where he’ll be sharing how Laser Force Cytology™ is advancing single-cell analysis and quality control in biomanufacturing.

September 24

At the 10th CAR-TCR Summit, LumaCyte’s Sean Hart redefines cell therapy analytics by introducing Laser Force Cytology, a label-free, real-time platform that shifts focus from cell viability to true cell vitality in CAR T manufacturing.

September 16–18

Join the LumaCyte team at Bioprocess International in Boston, September 16–18, and don’t miss President & CBO Renee A. Hart’s opening day panel, “Analytical Strategies for Next-Gen Biologics, Aligning Science and Regulation,” alongside industry leaders Hemant Kumar, Rajeev Boregowda, Ph.D., Kevin Zen, and Lior Shaltiel, Ph.D.

September 9–11

The LumaCyte team will be on site in Boston, September 9–11, for a week of innovation and insight, don’t miss President & CBO Renee A. Hart’s thought leadership discussion on how real-time PAT and predictive analytics are transforming biotherapeutic manufacturing with label-free cellular insights.

August 18-21

The LumaCyte team had a fantastic time at the Bioprocessing Summit in Boston on August 18-21, 2025, where our technology was honored as a Best in Show finalist and the spotlight was on advanced analytics, machine learning, and predictive modeling in biomanufacturing.

June 25

LumaCyte is proud to announce that President & CBO Renee A. Hart will Chair and moderate a powerhouse virtual panel titled “Uniting Analytical Innovation and Regulatory Excellence” on Wednesday, June 25 at 10 a.m. ET, featuring leaders from NIST, ELIQUENT Life Sciences, and US Pharmacopeia.

June 10 to 12

LumaCyte took the spotlight at CASSS CGTP 2025 in Boston, June 10–12, sharing how Radiance® is accelerating potency testing and precision bioprocessing through real-time, label-free analytics and AI-powered decision-making.

May 30

Join the LumaCyte team for the upcoming CHARM webinar on May 30, 2025, featuring Dr. Anna Kersey and Dr. Venigalla Rao in a dynamic discussion on advancing cell and gene therapy through regional collaboration and cutting-edge innovation.

May 13-17

The LumaCyte team had an incredible week at ASGCT 2025 in New Orleans, May 13–17, showcasing how Laser Force Cytology™ and Radiance® are transforming cell and gene therapy manufacturing through real-time, label-free analytics.

May 7–10

The LumaCyte team was honored to participate in ISCT 2025, May 7–10 in New Orleans, where we shared our vision for advancing cell therapy potency and predictive analytics with Laser Force Cytology™ and celebrated the community driving innovation in CGT.

April 21-24

Visit the LumaCyte team at the World Vaccine Congress Washington 2025 in Washington, DC.

April 7-9

Join LumaCyte’s team at the CASSS Bioassays: Scientific Approaches & Regulatory Strategies Symposium in Gaithersburg, MD.

January 28-30

Visit LumaCyte at the WCBP 2025 conference on January 28-30, 2025 in Washington, DC. Join us for an in-person seminar titled “Quantitative Cell Characterization Using Laser Force Cytology™ (LFC): The Future of Precision Analytics for Improved Manufacturing Success,” presented by Colin Hebert, LumaCyte, SVP Scientific and Business Operations. This insightful session will take place on Tuesday, January 28, 2025, from 12:25 PM to 1:25 PM.

January 20-23

Join the LumaCyte team at the Phacilitate Advanced Therapies Week (ATW) in Dallas, Texas. Visit us at Booth 448.

December 11-12

Join LumaCyte’s President and CBO Renee A. Hart at the 3rd annual PAT & Real Time Quality Summit in Philadelphia.

December 4

Join LumaCyte’s President and CBO Renee A. Hart at the 6th Annual Cell Therapy Analytical Development Summit. She will join Ramon Mendoza, Alexandre Ambrogelly, and Stephan O. Krause, PhD for the Industry Leaders’ Fireside Chat: Pioneering Analytical Frontiers to Overcome the Complexities of Cell Therapy Products – Insights from Cell Therapy’s Foremost Analytical Minds at 8:40 am on Wednesday, December 4.

December 3-5

Colin Hebert, Senior Vice President of Scientific & Business Operations at LumaCyte, will be presenting at the 6th Annual Cell Therapy Analytical Development Summit on Wednesday, December 4, 2024. Don’t miss his presentation at 12:30 pm titled “Quantitative Cell Characterization Using Laser Force Cytology™ (LFC): Predictive Insights into CAR T Donor Variability.”

December 2

BioPharm International invitated LumaCyte’s CEO and CSO, Sean Hart, PhD to participate in an industry expert panel, Fixing the Potholes in CGT Manufacturing. Listen in to hear Dr. Peter Marks, from CBER FDA, Fabian Gerlinghaus, from Cellares, Fyodor Urnov from Innovative Genomics Institute, share their perspectives and expertise on addressing the complexities associated with advanced therapy manufacturing.
Watch the interview.

November 19

Join LumaCyte for an exclusive webinar with ATCC and Malvern Panalytical, Ensuring Consistent Viral Product Quality Using Advanced Analytics to Characterize Viral Particle Count and Infectious Titer.

September 24-26

Join the LumaCyte team at the BioProcess International Conference in Boston, MA. BioProcess Insider’s State of the Industry Discussion – join Dan Stanton, Managing Editor, Bioprocess International, Olivier Loeillot, CEO, Repligen; Renee A. Hart, President & Chief Business Officer, LumaCyte and Andrew B. Harmon, MBA, PMP®, Senior Consultant, Latham BioPharm Group.

September 24-25

Join the LumaCyte team at the PDA – Parenteral Drug Association BioManufacturing Conference 2024 in Gothenburg, Sweden.

September 17-20

Join LumaCyte’s CEO and CSO, Sean Hart at the 9th Annual CAR-TCR Summit for a discussion on Tackling Variability to Progress Characterization of Heterogeneous Cell Products.

June 25

The PDA Vaccines Interest Group (VIG) would like to invite you to the webinar, Vaccine Manufacturing and the Adoption of Novel PAT Analytics, where senior vaccine manufacturing industry experts, Merck (MSD) manufacturing scientists and LumaCyte scientific leadership will be sharing case studies and novel insights about a new PAT platform (Laser Force Cytology™) which offers a replacement for traditional viral infectivity or titer assays like plaque assays and TCID50. Learn from the experts with a live Q&A session and see how innovation can be brought to vaccine manufacturing.

June 11-13

Join LumaCyte at the CASSS Cell & Gene Therapy Products Symposium at the Bethesda North Marriott Hotel & Conference Center in Rockville, MD.

May 29 – June 1

Join LumaCyte, a featured exhibitor, at ISCT 2024 in Vancouver. LumaCyte’s Sean Hart, PhD, CEO & CSO, will participate on an industry panel titled, “Current State and Future Directions of Process Analytical Technologies in the CGT Space.” 

May 19-24

Join LumaCyte at ECI Vaccine Technology IX at Secrets Puerto Los Cabos Resort.

May 6-11

Join LumaCyte, a featured exhibitor, at the ASGCT 27th Annual Meeting in Baltimore, MD. On May 8th at 1pm, stop by Booth#2227 for a Radiance® instrument demonstration by LumaCyte’s SVP of Scientific and Business Operations, Colin Hebert, titled “Real-Time, Label-Free, Cellular Fitness and Potency Measurements with Laser Force Cytology™.”

April 15-17

Join LumaCyte at CASSS Bioassays at the Gaithersburg Marriott Washingtonian Center in Washington, D.C.

April 1-4

Join LumaCyte, a Gold Sponsor, at World Vaccine Congress in Washington, D.C. LumaCyte will be hosting a roundtable entitled, “Precise Viral Quantification with Laser Force Cytology™ – Rapid Potency & Real-time PAT for Improved Process and Manufacturing Quality Control” with speakers: Renee Hart, LumaCyte President and CBO, Colin Hebert,PhD, SVP Scientific and Business Operations and Guy Pilkington, PhD, Senior Virologist and Group Leader, ATCC

March 28-29

Join LumaCyte at the PDA CDMO Partnership event in Long Beach, CA.

March 25-27

Join LumaCyte, a featured exhibitor, at the 2024 PDA Annual Meeting in Long Beach, CA.

March 17-20

Join LumaCyte, a featured exhibitor, at Advanced Therapies in ExCel, London.

March 11-13

Join LumaCyte, an event Gold Sponsor, at the 8th Annual Biopharmaceutical Emerging Best Practices Association (BEBPA) meeting in Long Beach, California. LumaCyte CEO and CSO, Sean Hart, PhD, gave an invited talk titled, Rapid & Precise Potency Assays using Label-Free Laser Force Cytology™.

February 22

Join LumaCyte at the USP/FDA Innovative Analytical Cell & Gene Therapy event at USP headquarters in Rockville, MD.

January 22-25

Join the LumaCyte team at the 2024 WCBP Symposium, which will be co-sponsored by the US FDA this year.

January 16-19

Come visit LumaCyte, a Silver Event Sponsor, at booth 347 at the Advanced Therapies Week.

December 5-7

Join the LumaCyte team at the 2nd Annual PAT & Real Time Quality Summit 2023 on December 5-7 in Boston, MA.

December 4-6

Join the LumaCyte team at the 5th Cell Therapy Analytical Development Summit on December 4-6 in Boston, MA.

November 1-3

LumaCyte’s President and CBO, Renee Hart was invited to present on Laser Force Cytology™ real-time process analytics, and how LumaCyte’s novel LFC technology is streamlining complex assays into early indicators of production success at NIST-FDA Workshops on Measurements and Standards for Advanced Therapy.

October 24

LumaCyte is incredibly proud to announce the launch of our newly redesigned Radiance® unit for space constrained manufacturing and QC labs. With only 16 inches of bench space required, this new unit utilizes the same powerful Laser Force Cytology™ technology to deliver real-time, single cell precision analytics to quantitatively characterize cellular starting materials and optimize key processes throughout the complex manufacturing of life saving advanced therapies. Read full press release.

September 18-21

Join the LumaCyte team at the BioProcess International Conference in Boston.

August 29 – September 1

Join the LumaCyte team at the 8th CAR-TCR Summit in Boston, MA.

August 14-19

Join LumaCyte’s Senior Vice President, Scientific and Business Operations, Colin Hebert, PhD on Tuesday August 14 at 8:30 am for a Presenation on the Development, Bioprocessing, and Manufacturing of Advanced Therapies: Laser Force Cytology as a Process Analytical Technology (PAT) to Improve the Efficiency and Consistency of Biologics Research, Development, and Production.

August 13

LumaCyte featured in the August issue of Genetic Engineering & Biotechnology News. Check out GEN’s latest insights: Label-Free Cell Analysis with Laser Force Cytology; Real-time process analytical technology for accelerated biologics development and improved manufacturing consistency.
Read the full article.

June 27-29

Join our team at the debut CGTP Summit in Rockville, MD. Join our team at the ISBioTech 12th Spring Meeting in Norfolk, Virginia.

June 7-8

Join exhibits at the 2023 PDA Advanced Therapy Medicinal Products Conference in  Baltimore, MD.

May 9-12

Join the LumaCyte team at the BioProcess International Europe Conference & Exhibition. Stop by Booth 126 to meet our team!

April 3-6

LumaCyte is a proud Gold Sponsor of the 2023 World Vaccine Congress Washington: R&D + Strategic Partnering For The Global Vaccine Industry being held in Washington, DC April 3-6. Please come out and meet our team!

March 20-22

Join our team at the ISBioTech 12th Spring Meeting in Norfolk, Virginia

January 17-20

Phacilitate Advanced Therapies Week, Miami Beach Convention Center Join LumaCyte senior executives in Miami this month to learn how Laser Force Cytology is transforming key bioprocess and production assays across the growing cell and gene therapy and vaccine landscapes. Visit us LumaCyte (Bronze Sponsor) at booth 634!

December 1-2

LumaCyte CEO and CSO to speak opening morning at 10am, PAT & Real Time Quality Summit: A Quality by Design Approach with Laser Force Cytology Real-time Predictive Analytics. LumaCyte is proud to be the lead sponsor at the inaugural PAT & Real Time Quality Summit being held in San Diego. Please join Renee Hart, LumaCyte’s President and Chief Business Officer, as she discusses along with industry colleagues the importance of actionable analytics

September 27-30

LumaCyte to exhibit as a bronze sponsor at the annual Bioprocess International conference in Boston, MA

July 26-28

Sean Hart, PhD, Renee A. Hart, and Colin Hebert from the LumaCyte team were invited to talk and to share a poster at the NIIMBL 2022 National Meeting.

July 15

GEN sponsored webinar featuring Dr. Peter Marks, MD, PhD, who will be discussing the growing need for improved production and product consistency through better analytical data. The biopharma industry is evolving at an accelerated rate driving with it the need for faster, more precise analytics. Biomanufacturing veteran, James Robinson, will also share industry case studies illustrating how accurate analytics provided in real-time can significantly improve production outcomes and quality.

June 12-17

LumaCyte’s Poster Accurate and Precise Viral Quantification for Rapid Vaccine Development and In-Process Production Monitoring using Radiance® Laser Force Cytology™ was at the ECI Vaccine Technology VIII Conference in Sitges, Spain.

May 3

Read the latest newsletter from GEN Genetic Engineering & Biotechnology News. LumaCyte Advances in BioProcessing: Digitization, Vaccine Developments, and the FDA Seeks Consistency.

March 1

Jim Robinson, Scientific Advisory Board, LumaCyte and former Chair of CEPI Scientific Advisory Committee and Colin Hebert, VP Biotechnology, LumaCyte to host round table discussion with industry production scientists, Real-time Bioprocess Analytics Delivering Improved Production Consistency and Increased Product Yields at the 2022 World Vaccine Congress in Washington, DC April 19 at 11:30 and 12:45.

January 11

LumaCyte Laser Force Cytology (LFC) was recently published in Springer Method, Vaccine Delivery Technology book where a full chapter is dedicated to Radiance and LFC rapid viral infectivity quantification assay.

January 26

Lumacyte CSO, Sean Hart, PhD and Catalent Pharma Solutions Director of Internal R&D & Product Development, Bhargavi Kondragunta, Ph.D. were featured speakers at the Fierce Biotech Webinar: Are Real-Time Gene Therapy Test Results Possible?

September 29

Cells were infected two hours post seeding and then harvested for analysis with Radiance at 48 hours post infection in two separate experiments in order to demonstrate LFC’s ability to quantify adenovirus infection in HEK 293 cells. Read the Technical Note: Radiance® Label-Free Monitoring of Adenovirus Infection of HEK293 Cells.

October 6

NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals invited Renee Hart, LumaCyte’s President & CBO, to present to NIIMBL’s pharma, CDMO, and government members on the value of Laser Force Cytology in accelerating vaccine development and production.

September 30

LumaCyte is awarded Highly Commended for the Best Production/Process Development Award at the World Vaccine Congress Vaccine Industry Excellence (VIE) Awards.

September 28 – October 1

LumaCyte is a Gold Sponsor, Speaker, and Exhibitor at the World Vaccine Congress Virtual Event.

September 14

LumaCyte’s CEO & CSO Sean Hart, PhD discusses how to “Overcome Vaccine Production Bottlenecks with Real-time Infectivity – When Saving Time Means Saving Lives” at the World Vaccine Congress.

March 30

LumaCyte Laser Force Cytology demonstrates detection of human coronavirus (OC43) infectivity using its Radiance instrument. Rapid detection of infectivity is critical for proper assessment of vaccine candidates, manufacturing, inactivation, and formulations testing. Read the Tech Note.

March 20

LumaCyte achieves Underwriters Laboratories U/L certification for electrical and safety for Radiance +Autosampler products.

February 1

LumaCyte welcomes Dr. Christof Hasse as Executive Director Business Development, – Europe. Christof comes to LumaCyte with 25 years’ experience in biopharma analytical instrumentation.

January 7

LumaCyte was awarded the Frost & Sullivan 2019 Global Single-Cell Analysis New Product Innovation Award for Its Novel Laser Force Cytology™ Technology.

September 12

LumaCyte primed for significant global growth: CE mark opens European market. LumaCyte an advanced research and bioanalytics instrumentation company headquartered in Charlottesville, VA, announces third doubling of their manufacturing and laboratory space.

June 1

LumaCyte will be a Platinum sponsor and exhibitor at the European Society of Cell & Gene Therapy (ESGCT) congress in Barcelona on October 22-25, 2019.

May 1

LumaCyte to sponsor and exhibit at the World Vaccine Congress Europe in Barcelona, October 28-31, 2019

April 22

LumaCyte sponsors ECI Vaccines VIII in Barcelona, Spain, in June, 2020.

April 15

LumaCyte to exhibit at the Generis American Biomanufacturing Summit in San Francisco on June 18-19, 2019.

April 16

LumaCyte was awarded the Best Production/Process Development 2019 Vaccine Industry Excellence Award.

April 14-17

LumaCyte’s CEO, Sean Hart, PhD, and Gray Heppner, MD, FACP, FASTMH, from LumaCyte’s Scientific Advisory Board, lead the Interactive Round Table discussion on Replacing antiquated assays with rapid viral vaccine infectivity measurements and process analytical technologies (PAT) at World Vaccine Congress in Washington DC.

April 8

LumaCyte executives participated in the 2019 BioHealth Capital Region Forum as they discussed New Tools in Therapeutics with GSK, Arcellx, MaxCyte, Inc. and Serpin Pharma.

April

Radiance +Autosampler achieves European Economic Area (EEA) health, safety and environmental protection standards to support growing global demand.

March 14

LumaCyte to participate in the Virginia Bio Commercialization Luncheon, “Dynamic Duo Lights the Way to Cell Discovery” on Thursday, March 14, 2019 at the Virginia Bio+Tech Park.

March 7

LumaCyte was selected as a finalist for this year’s Vaccine Industry Excellence (ViE) Awards on April 15, held in conjunction with the 19th World Vaccine Congress, April 14-17 in Washington D.C. for the category of “Best Production/Process Development Award”.

March 6

Dr. Delphine Le Roux’s technology poster was voted ‘top 5 best posters’ by the meeting attendees at ISBiotech’s 9th Spring Meeting in Norfolk, VA.

March 4

Dr. Colin Hebert presented a technology workshop at ISBiotech’s 9th Spring Meeting in Norfolk, VA: From Vaccines to Cell Therapy Biomanufacturing: Applications of Laser Force Cytology for Rapid Viral Infectivity Measurements and Label-Free Biomarker Development.

March 4-6

LumaCyte attends ISBiotech’s 9th Spring Meeting in Norfolk, VA.

February 21

LumaCyte to host a roundtable discussion at the World Vaccine Congress in Washington, DC on April 18, 2019. The roundtable, Replacing antiquated assays with rapid viral vaccine infectivity measurements and process analytical technologies (PAT), will be moderated by Drs. Gray Heppner and Sean Hart.

February 15

LumaCyte to Gold Sponsor the World Vaccine Congress in Washington DC, Walter E Convention Center, April 6-9, 2020. This will be our fifth year at the event and we look forward to seeing you there!

February 5

LumaCyte to exhibit and attend Generis American Biomanufacturing Summit in San Francisco, June, 2019.

January 25

LumaCyte to exhibit at World Vaccine Congress Europe in Palau de Congressos de Catalunya, Barcelona, Spain, October 29-31, 2019.

January 20

LumaCyte nominated for this year’s Vaccine Industry Excellence (ViE) Award for the category of “Best Production/Process Development Award”.

January 9

LumaCyte wins National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) grant for workforce development entitled, “Characterization of Cell Therapy Products by Flow and Laser Force Cytometry” with Rensselaer Polytechnic Institute and Celgene.

January 7-9

LumaCyte executives attend JP Morgan Healthcare Week Conferences in San Francisco.

December 12

LumaCyte’s Radiance instrument was used to support new immunotherapy research for melanoma. Read the new oncolytic virus immunotherapy paper in Science Translational Medicine to learn more.

December 12

LumaCyte was invited to give a talk at the MIT Center for Biomedical Innovation’s 2018 BioMAN Summit in Boston. Our Vice President, Dr. Colin Hebert gave a presentation on Cellular Biophysical Characterization for Cell and Gene Therapy.

November 14

LumaCyte CEO/CSO was a co-author on National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) vaccines biomanufacturing roadmap produced by BioPhorum Operations Group (BPOG). Dr. Hart led the Analytical, Modeling, and Knowledge Management sections writing about the use of new analytical technologies and methods for advanced vaccine biomanufacturing.

October

Dr. Colin Hebert participated in the NIIMBL adventitious agent testing (AAT) meeting at Merck.

September 12

LumaCyte publishes peer-reviewed article in the journal Vaccine detailing the use of their Radiance instrument for rapid viral infectivity measurements with vesicular stomatitus virus (VSV) as a replacement for TCID50.

September 4

LumaCyte, one of the recipients of NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals’s Quick Start Project (QSP) Award, is collaborating with Genetech & Carnegie Mellon University on a project focused on Adventitous Agent Testing.

August 30

LumaCyte announces the award of a project through National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) for adventitious agent testing (AAT) with Genentech and Carnegie Mellon University.

August 7

Renee Hart, LumaCyte’s President & Chief Business Officer was invited to present on the Healthcare Businesswomen’s Association (HBA) Career Conversations Webinar. With record webinar attendance levels, Renee shared insights and experience that could benefit other women as they strive to accelerate their careers.

June 21

LumaCyte’s CEO Sean Hart presenting on Laser Force Cytology and applications in vaccine development and production at ECI Conference, Vaccine Technology VII in Mont Tremblant, Quebec, Canada.

May 15

Dr. Sean J. Hart, LumaCyte CEO invited to present at Ideagen’s Annual Global Leadership 2030 Summit on the Power Panel: Disruption 2030, focused on healthcare innovation at Gallup’s Headquarters in Washington, DC June 7th, 2018.

May 4

LumaCyte to exhibit at the World Vaccine Congress in Washington DC, April 14-17, 2019. This will be our fourth year at this event and we look forward to seeing you there!

May 1

LumaCyte invited to join the Advanced Virus Detection Technologies Interest Group (AVDTIG). This group is dedicated to finding new and advanced methods for the rapid detection of adventitious viruses to ensure biologic drug safety. [5]

April 15

LumaCyte to sponsor and present at the ECI Conference, Vaccine Technology VII [6] on June 17-22, 2018 in Mont Tremblant, Quebec, Canada.

April 10

LumaCyte to attend the NIIMBL National Meeting [7] in Washington DC April 15-16 at the National Academy of Sciences [8].

April 3

LumaCyte exhibited and attended the World Vaccine Congress in Washington DC. Thank you to our customers, both new and existing, for visiting with us and discussing applications of our products & technology.

April 1

LumaCyte wins grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) for Adventitious Agent Detection (AAT).

February 15

LumaCyte launches their Single Cyte Blog – dedicated to all things single cell analysis. Check back often for article reviews, news, technology highlights, and more.

February 1

LumaCyte welcomes Ms. Carolyn Maki as our Vice President of Business Development & Partnerships. Carolyn joins us from PPD where she was Executive Director, BD for Central Labs.

January 12

LumaCyte’s VP of biotechnology, Dr. Colin Hebert, presented a workshop entitled “Laser Force Cytology: A Novel Technology for Rapid Quantification of Viral Infectivity and Label-Free Cellular Analysis” at International Society for Bioprocess Technology, ISBioTech’s spring meeting on March 5th, 2018 in Norfolk, VA.

January 4

LumaCyte to present at the 2018 World Vaccine Congress in Washington DC April 3-5, 2018.

December 19

LumaCyte featured in National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) monthly newsletter.

December 1

LumaCyte welcomes Dr. Margaret McCoy, PhD, JD as Executive Director Assay Development & Regulatory Affairs. Dr. McCoy will lead clinical application and product development and also coordinate regulatory matters.

November 15

LumaCyte welcomes Keya Rodrigues, MS as a bioengineer. Ms. Rodrigues will work on applications development using Laser Force Cytology and new product R&D.

October 3

LumaCyte’s Drs. Colin Hebert and Sean Hart co-publish paper with scientists at the Naval Research Laboratory (NRL) on macrophage phagocytosis detection and monitoring using laser optical forces. Read more here.

September 1

LumaCyte welcomes Thang Nguyen, MS, as a senior software engineer. Mr. Nguyen is a certified LabVIEW Architect and LabVIEW instructor and will work on development of software for LumaCyte’s products and applications.

May 15

LumaCyte announces that is a founding sponsor of the CvilleBioHub. The CvilleBioHub is an organization that was created to connect and help grow the biotech and life sciences communities, while bringing awareness of the Charlottesville area as a biotech center in central Virginia.

April 11

LumaCyte unveils and demonstrates its much anticipated 96 well plate autosampler at the World Vaccine Congress.

April 10

LumaCyte & Thermo Fisher Scientific presented a poster entitled, “Rapid Quantification of Vesicular Stomatitis Virus Infectivity in Vero Cells using Laser Force Cytology”, at the World Vaccine Congress.

April 10

LumaCyte & Rutgers Cancer Institute of New Jersey (CINJ) presented a poster entitled, “Monitoring the Oncolytic Effect of Talimogene laherparepvec (T-VEC) in combination with the MEK inhibitor Trametinib using Laer Force Cytology”, presented at the World Vaccine Congress.

April 10-12

LumaCyte exhibits at the World Vaccine Congress in Washington, DC.

March 6-8

LumaCyte and Nanotherapeutics, Inc. presented a poster entitled, “Rapid Quantification of Viral Infectivity in a Recombinant Baculovirus System using Laser Force Cytology” at the ISBiotech Spring 2017 meeting in Washington, DC.

December 28

LumaCyte signs Material Transfer Agreement (MTA) with the United States Army Medical Research Institute for Infectious Diseases (USAMRIID). LumaCyte is collaborating with USAMRIID using Radiance instrument for the analysis of Zika virus infected mammalian cells for rapid infectivity and neutralization assays.

December 16

LumaCyte was excited and honored to be present for the announcement of the nearly $200 million National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) at the University of Delaware.

December 12

LumaCyte’s role in Zika R&D featured in newspaper article.

December 1

LumaCyte featured in NBC29 nightly news segment on Zika virus research.

November 15

LumaCyte to present at CVille Biohub’s Zika Virus Forum in Charlottesville, VA, December 1, 2016.

August 8

LumaCyte will exhibit at the World Vaccine Congress in Washington DC, April 10-12, 2017.

August 2

LumaCyte invited to present keynote address in the Vision Summit Meeting at National Instruments’ conference in Austin, TX on August 2-4, 2016

March 3

Join LumaCyte at their exhibit booth #13 at the World Vaccine Congress 2016 in Washington DC, March 29-31, 2016.

February 26

LumaCyte is please to announce its inclusion and participation in the Zika Response Working Group.

September 23

LumaCyte to sponsor and exhibit at the World Vaccine Congress 2016 in Washington DC, March 29-31, 2016.

September 15

LumaCyte to sponsor and present at the Vaccine R&D 2015 Conference, November 2-4, 2015 in Baltimore, MD.

August 2

Article published in Cytofluidix, an online microfluidics technology review.

March 16

Dr. Sean J. Hart to present the keynote lecture at Suffolk University’s annual STEM Reception on April 27, 2015.

February 23

Dr. Sean J. Hart to present at Mid-Atlantic Directors & Staff of Scientific Cores Meeting.

February 1

LumaCyte welcomes Dr. Colin Hebert to the team as Vice President, Biotechnology. Dr. Hebert comes to LumaCyte from the Bio/Analytical Chemistry Section at the Naval Research Laboratory (NRL) where he collaborated with LumaCyte to develop their novel label-free cell analysis and sorting technology.

January 1

LumaCyte has moved into its new biosafety level two (BSL-2) laboratory and office in Charlottesville.

May 10

LumaCyte has delivered its first prototype cell analysis and sorting instrument to the flow cytometry core facility at the University of Virginia (UVA) School of Medicine for testing.

March 5

LumaCyte has entered into a Collaborative Research and Development Agreement (CRADA) with the Naval Research Laboratory (NRL), Washington, DC for the development of optical instrumentation for cell analysis and sorting.

January 18

LumaCyte establishes collaboration with medical researchers at the University of Virginia (UVA) School of Medicine.

January 6

Dr. Sean J. Hart will be presenting an invited talk at NanoTech in June 2014. His presentation will be focused around disease detection and characterization in mammalian cells using our novel cell analysis and sorting system currently under development.